References
- Telio D, Fernandes K, Ma C, . Salvage chemotherapy and autologous stem cell transplant in primary refractory diffuse large B-cell lymphoma: outcomes and prognostic factors. Leuk Lymphoma 2011;52:833–838.
- Gisselbrecht C, Glass B, Mounier N, . Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 2010;28:4184–4190.
- Josting A, Reiser M, Rueffer U, . Treatment of primary progressive Hodgkin's and aggressive non-Hodgkin's lymphoma: is there a chance for cure? J Clin Oncol 2000;18:332–339.
- Chen YB, Hochberg EP, Feng Y, . Characteristics and outcomes after autologous stem cell transplant for patients with relapsed or refractory diffuse large B-cell lymphoma who failed initial rituximab, cyclophosphamide, adriamycin, vincristine, and prednisone therapy compared to patients who failed cyclophosphamide, adriamycin, vincristine, and prednisone. Leuk Lymphoma 2010;51:789–796.
- Vose JM, Zhang MJ, Rowlings PA, . Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 2001;19:406–413.
- Hamlin PA, Zelenetz AD, Kewalramani T, . Age-adjusted International Prognostic Index predicts autologous stem cell transplant outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. New Engl J Med 2002;346:1937–1947.
- Kasamon YL, Wahl RL, Ziessman HA, . Phase II study of risk-adapted therapy of newly diagnosed, aggressive non-Hodgkin lymphoma based on midtreatment FDG-PET scanning. Biol Blood Marrow Transplant 2009;15:242–248.
- Trneny M, Bosly A, Bouabdallah K, . Independent predictive value of PET-CT pre-transplant in relapsed and refractory patients with CD20 diffuse large B-cell lymphoma (DLBCL) included in the CORAL study. Blood 2009;114(Suppl. 1): Abstract 881.
- Moskowitz CH, Schöder H, Teruya-Feldstein J, . Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in advanced-stage diffuse large B-cell lymphoma. J Clin Oncol 2010;28:1896–1903.
- Rosenwald A, Wright G, Chan WC, . The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002;346:1937–1947.
- Witzig TE, Vose JM, Zinzani PL, . An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Ann Oncol 2011;22:1622–1627.
- Honigberg LA, Smith AM, Sirisawad M, . The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA 2010;107:13075–13080.